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OBJECTIVES: Schizophrenia is a chronic illness with great eco-
nomic burden. Paliperidone ER is a new atypical antipsychotic
drug in Turkey. The aim of the study is to estimate the cost-
effectiveness of paliperidone ER compared to other oral atypi-
cals (risperidone, olanzapine, quetiapine, ziprasidone and
aripiprazole) in acute phase of schizophrenia. METHODS:
Model: An existing decision analytic model is adapted (based on
literature and expert panels). The time horizon is six weeks. The
study is performed from the health care payer perspective.
Patient group: Patients diagnosed with schizophrenia that have
suffered an acute exacerbation. Data sources: The clinical data
are acquired from the literature. Resource use data are derived
via expert panel. Prices of medications, institutional discount
rates and other costs related to the treatment are obtained from
Ministry of Health Drug Price List, Price List of Social Security
Institution Health Implementation Guideline Appendix 2/D, 8
and 9, respectively. Clinical and economic outcomes: The clini-
cal outcome measure is the number of patients responding. The
response rate describes the proportion of patients who beneﬁted
from the therapy. This is deﬁned as those achieving decrease of
30% or above to baseline in total PANSS score. Only direct
medical costs, i.e. costs of antipsychotics, treatment of side
effects, physician visits, hospitalization and laboratory exami-
nations are considered. The results are presented as (ICER)
additional cost per additional patient responding. RESULTS:
Results are as follows: Total costs: €488, €444, €459, €629,
€732, €712; response rates: 0.42, 0.36, 0.41, 0.33, 0.30, 0.32
for paliperidone, risperidone, olanzapine, quetiapine, ziprasi-
done and aripiprazole respectively. ICER is €760/responder for
paliperidone. One-way sensitivity analyses prove that results of
the study are strong. CONCLUSIONS: In the acute phase of
schizophrenia, paliperidone is the dominant therapy in compari-
son to quetiapine, ziprasidone and aripiprazole. Compared to
risperidone and olanzapine, it is the cost-effective therapy
option.
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OBJECTIVES: The Welsh National Database on Substance
Misuse (WNDSM) has recorded around 1000 new referrals per
quarter for patients requiring treatment for their opioid abuse
problemwith little evidence to suggest that numbers are declining.
Opioid dependence in Wales is currently mostly treated with
buprenorphine (Subutex) and methadone. Both of these therapies
have their associated problems, notably the diversion of buprenor-
phine to the black market and its abuse through crushing, dissolv-
ing and injecting. The cost-effectiveness of buprenorphine/
naloxone (Suboxone), a formulation of buprenorphine containing
a component to deter abuse, has been appraised in Scotland but
not in Wales. METHODS: A decision analytic model was devel-
oped to evaluate the cost-effectiveness of buprenorphine/naloxone
in theWelsh treatment setting. Clinical data were sourced from an
unpublished trial comparing buprenorphine/naloxone andmetha-
done as well as from a long-term safety trial of buprenorphine.
Themodel takes into account expected pharmacy costs of dispens-
ing and supervision. The base case assumed that buprenorphine/
naloxone would be supervised less frequently than methadone or
buprenorphine due to its reduced potential for abuse. RESULTS:
The base case analysis found buprenorphine/naloxone to be cost-
effective compared with methadone (ICER £26,775/QALY), and
dominant compared to buprenorphine which is priced identically.
Since all three treatment options have similar efﬁcacy, these ﬁnd-
ings are attributable mainly to the reduced need for supervision of
buprenorphine/naloxone compared to other substitution thera-
pies. CONCLUSIONS: As was found in the Scottish system,
buprenorphine/naloxone appears to be a cost-effective treatment
option compared to methadone and buprenorphine alone.
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OBJECTIVES: Long-term pharmacologic treatment of schizo-
phrenia is critical towards optimizing outcome. The objective of
this study is to estimate the cost-effectiveness of paliperidone ER
in the long-term treatment of schizophrenia compared to other
oral atypical antipsychotic drugs (risperidone, olanzapine,
quetiapine, ziprasidone and aripiprazole) in Turkish setting.
METHODS: Model: An existing decision analytic model is
adapted (based on literature and expert panels). The time
horizon is one year. The study is performed from the health care
payer perspective. Patient group: Community dwelling patients
with schizophrenia who have suffered an acute exacerbation.
Data sources: The clinical data are acquired from the literature.
Resource use data are derived via expert panel. Prices of medi-
cations, institutional discount rates and other costs related to
the treatment are obtained from Ministry of Health Drug Price
List, Price List of Social Security Institution Health Implemen-
tation Guideline Appendix 2/D, 8 and 9, respectively. Clinical
and economic outcomes: The clinical outcome measures are the
proportion of patients relapsing, number of stable days and
number of functional stable days. Only direct medical costs, i.e.
costs of antipsychotics, treatment of side effects, physician visits,
hospitalization and laboratory examinations are considered.
RESULTS: Clinical and economic results are as follows: Total
costs: €1959, €1852, €1903, €2396, €2627, €2630; number of
relapses: 1.80, 2.03, 1.84, 2.14, 2.26, 2.22; number of stable
days: 223, 207, 219, 198, 186, 188; number functional stable
days: 152, 142, 146, 112, 106, 113 for paliperidone, risperi-
done, olanzapine, quetiapine, ziprasidone and aripiprazole,
respectively. ICER values are of 6.85€/stable day; €10.03/
functional stable day; €478.70/prevented relapse for paliperi-
done. One-way sensitivity analyses prove that results of the
study are strong. CONCLUSIONS: In the long-term treatment
of schizophrenia, paliperidone is the dominant therapy in com-
parison to quetiapine, ziprasidone and aripiprazole. Compared
to risperidone and olanzapine, it is the cost-effective therapy
option.
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